Search Results
Results found for "G protein-coupled receptors"
- How GPCR Collaboration Built an Innovation Engine
flipped that logic: Shared infrastructure, not duplicated equipment Centralized core facilities for receptor That gave them capabilities others couldn’t match — from receptor biosensor platforms to live-cell imaging
- Inside Out: Mapping GPCRs from Membrane Codes to Market Moves
tagging to scalable multiplex assays, this conversation dives deep into the tools now transforming receptor
- First in Human: Early-stage COVID therapies hold promise against omicron variant
partner GlaxoSmithKline PLC posted results Dec. 7 demonstrating activity against the omicron spike protein
- Targeting mGluR2/3 for treatment of neurodegenerative and neuropsychiatric diseases
Glutamate exerts its effect through ionotropic and metabotropic glutamate receptors (mGluRs). mGluR2 drug targets for the treatment of many neurological conditions and several compounds targeting these receptors
- Are You Guessing or Forecasting? Master GPCR Pharmacologic Models Before It’s Too Late
. ✅ Future-proof your career: Conquer complex laws and understand where receptor theory is going next
- CCL25/CCR9 interaction promotes the malignant behavior of salivary adenoid cystic carcinoma via...
behavior of salivary adenoid cystic carcinoma via the PI3K/AKT signaling pathway "Background CC chemokine receptor 9 (CCR9), an organ-specific chemokine receptor, interacts with its exclusive ligand CCL25 to promote
- Chronic itch: emerging treatments following new research concepts
Current progress in our knowledge of the itch processing, the numerous mediators and receptors involved Currently, inhibitors of IL-31, IL-4/13, NK1 receptors, opioids and cannabinoids, JAK, PDE4 or TRP are
- The Five Traps of Ignoring Kinetics
offset rate, using rapid calcium assays Potency Is a Ratio of Rates Two ligands compete for the same receptor monophasic curves, you’ll see biphasic signatures or sequential shifts—first cholinesterase inhibition, then receptor
- Engineered synaptic tools reveal localized cAMP signaling in synapse assembly
We show that locally restricted suppression of postsynaptic cAMP levels or of cAMP-dependent protein-kinase
- SYnAbs is now officially accredited as a Research Tax Credit by the French Ministry of Higher...
trust us in the generation of their monoclonal antibodies against small molecules and transmembrane receptors
- Modulation of Striatal Adenosinergic Function by HTL0041178, a Selective GPR52 Agonist
novel GPR52 agonist HTL00411718 to modulate centrally mediated locomotor activity in response to A2A receptor
- Trevena Announces Advancement of TRV045 Into Clinical Development for Diabetic Neuropathic Pain
TRV045 is the Company’s novel S1P1 receptor modulator being developed as a potential treatment for diabetic
- C3aR plays both sides in regulating resistance to bacterial infections
results in the production of bioactive C3a, a product of C3 cleavage, which interacts with membrane-bound receptor
- Maria’s Travel Blogs: ACSMEDI-EFMC Medicinal Chemistry Frontiers 2025
The talks given targeted both traditional GPCRs such as the serotoninergic receptor 5HT1A, but also newer
- Addex Therapeutics Completes Patient Enrollment For Dipraglurant Blepharospasm Phase 2 Clinical ...
Dipraglurant selectively targets the metabotropic glutamate receptor subtype 5 (mGlu5) through allosteric
- Addex Expands Pipeline With Selective M4 Positive Allosteric Modulator Program For The Treatment ...
drug discovery and development, announced today that it has moved a selective and potent M4 muscarinic receptor
- Dynamics of tumor-associated macrophages in a quantitative systems pharmacology model of...
Quantitative systems pharmacology (QSP) modeling is an emerging mechanistic computational approach that couples
- Search for safer pain relief advances with new engineered compounds
pain-relieving compounds that, like morphine and other drugs, provide relief via activation of opioid receptors
- California gold rush for Sosei Heptares
The vision is to develop novel muscarinic receptor agonists for schizophrenia and other neuropsychiatric
- Molecular basis for variations in the sensitivity of pathogenic rhodopsin variants to 9-cis-retinal
Evaluation of the observed shifts relative to thermodynamic estimates for the coupling between binding
- Neuropeptide S Encodes Stimulus Salience in the Paraventricular Thalamus
Taking advantage of a striking deficit of both NPS receptor (NPSR1) and NPS precursor knockout mice in
- Positive Recommendation for Use of TAVNEOS™ (avacopan) in ANCA Vasculitis Adopted by European ...
authorization for the Company’s TAVNEOS (avacopan), an orally administered selective complement 5a receptor
- Addex's strategic partner The Janssen Pharmaceutical Companies of Johnson & Johnson, Inc. has...
ADX71149 is a selective metabotropic glutamate type 2 (mGlu2) receptor positive allosteric modulator
- Irreversible Drugs, Real Control: Design for Durable Target Engagement
Must-read publications: AT1R β-arrestin bias; UII receptor structure; β2AR constant-pH dynamics. Your Membership Gives You: Proven frameworks used in real discovery programs On-demand lessons built
- Better GPCR Drug Discovery Decisions Start With Structured Learning
Must-read publications: D2 receptor constitutively active mutants; β2AR allosteric SERS assay; CXCR4 Terry Kenakin walks through the core early assays that protect your chemistry, budget, and timeline.
- Mechanism vs. Assumption: A Model-First Path to Getting GPCR MoA Right
Physiological relevance: Fluorescent ligands can retain receptor integrity—critical when signaling readouts
- From Snapshots to Predictions: Why Mechanism of Action Matters
What happens when receptor expression is different? What happens in vivo? Are Models Ever Proven? Here’s the uncomfortable truth: you can never prove a model “right.”










